62 results about "Meibomian gland dysfunction" patented technology

The present disclosure provides compounds and pharmaceutically acceptable salts thereof for inhibiting CYP26B1. Aspects of the present disclosure also include methods of using the compounds to treat diseases or disorders, including, but not limited to, skin disorders, cancer, neurological disorders, heterotopic ossification (HO), fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas, and diseases or disorders of the eye, including meibomian gland dysfunction and dry eye disease.

The invention relates generally to the field of medical devices and, more specifically, to a handheld device that stimulates the meibomian gland of the eyelid mechanically, and specifically stimulates the meibomian glands of the eyelid to treat Meibomian gland dysfunction, also known as “Dry eye” and chronic marginal eyelid inflammation.

The invention discloses an ultrasonic image evaluation processing method and device for meibomian gland dysfunction, and relates to the technical field of data processing. A meibomian gland dysfunction disease classification model is constructed based on a lightweight first-order index integral method decoder module and a second-order explicit Adams method decoder module; and the identification capability of the meibomian gland classification model on a high-noise region and a small target region in the ultrasonic image is improved, so that the meibomian gland in the ultrasonic image can be subjected to high-precision classification evaluation processing by the meibomian gland dysfunction disease classification model. Due to the adoption of the lightweight decoder module, the model parameters of the meibomian gland dysfunction classification model are reduced, and the scale is lighter, so that the occupation of computing resources during the operation of the meibomian gland dysfunction classification model is reduced. The encoder-decoder model is trained after the unlabeled data set is pre-trained based on the fine tuning data set, so that self-supervised training of the meibomian gland dysfunction disease classification model is realized, and the training cost and time are reduced.

The present invention relates to: a composition for preventing, alleviating or treating dry eye syndrome or meibomian gland dysfunction; and the like, and was completed by identifying the excellent effects of treating dry eye syndrome with 1,5-O-dicaffeoylquinic acid and improving meibomian gland function. 1,5-O-dicaffeoylquinic acid, a key component of the present invention, reduces corneal epithelial loss, increases the amount of tear production, inhibits inflammation of the lacrimal and meibomian glands, increases the area of the meibomian gland, increases the survival rate of corneal epithelial cells in a hyperosmotic environment, and can inhibit cell death. Therefore, the composition according to the present invention can effectively treat dry eye syndrome caused by environmental stress or various diseases and improve meibomian gland function, and thus is expected to be used as a therapeutic agent for various eye diseases.

The present disclosure provides an eye disease model animal, a method for producing the eye disease model animal, and a method for screening therapeutic agents and / or prophylactic agents for dry eye. One aspect of the present disclosure provides a dry eye model animal that has a characteristic associated with meibomian gland dysfunction. Another aspect of the present disclosure provides a method for producing the dry eye model animal, the method including a step for transplanting cells from an animal that is allogeneic to the dry eye model animal into an animal that has reduced or deficient immune function.

The present invention relates to use of a multifunctional isoquinoline ligand, namely 1-(7-amino-4,5,6-triethoxy-1-oxo-1,3-dihydro-3-isobenzofuran)-8-methoxy-2-methyl-6,7-methylenedioxy-2,3,4-tetrahydroisoquinoline or tritoquinoline, for treating dry eye, meibomian gland dysfunction and lacrimal gland dysfunction.

The invention relates to the technical field of cell biology, and particularly discloses an isolated culture method of primary meibomian gland epithelial cells, the obtained primary meibomian gland epithelial cells and application of the primary meibomian gland epithelial cells. The method comprises the following steps: efficiently and mildly digesting meibomian gland tissues by adopting a compound digestive juice consisting of I-type collagenase, dispersing enzyme and trypsin in a specific ratio; stopping digestion by using a serum-containing neutralizing solution and collecting cells; the method comprises the following steps: promoting cell attachment by using a serum-containing initial culture medium, and carrying out selective amplification by using a serum-free proliferation culture medium to finally obtain high-purity and high-activity primary meibomian gland epithelial cells. The method solves the problems of long digestion time, low cell yield, poor purity and the like in the traditional method. The obtained cell can be used for constructing a meibomian gland dysfunction model, screening drugs and researching lipid metabolism, and an important technical platform and a cell model are provided for research and treatment of related eye diseases.

The present invention relates to the use of the isoquinoline multifunctional ligand amino-7 triethoxy-4,5,6 oxo-1 dihydro-1,3 isobenzofuranyl-3)-1 methoxy-8 methyl-2 methylenedioxy-6,7 tetrahydro-2,3,4 isoquinoline or tritoqualine for the treatment of dry eye, meibomian gland dysfunction and lacrimal gland dysfunction.

Embodiments provide a moldable warming device, including: a heating disc; a pair of stimulation vibration generators; a coupling device; and an ocular and periocular treatment platform, the ocular and periocular treatment platform being head mounted and forehead stabilized. The moldable warming device is configured to sequentially and alternately apply therapeutic warmth to meibum within each Meibomian gland duct in all four eyelids and, and further configured to simultaneously apply tuned harmonic resonance or non-resonance frequency stimulation vibration across the contour of the entire surface of the user's four eyelids and periorbital structures and across the contour surface of the user's nasal bridge area through the user's nasal bone, after the heating disc has lowered the lipid viscosity within each Meibomian gland duct, to induce expression of shear thinned and liquified meibum from each Meibomian gland duct in all four eyelids to improve the lipid layer of the surface of the user's eye tear film.

The present disclosure provides compositions for use in the treatment of eye-related conditions (e.g., conditions that affect the meibomian gland). Compositions for use in such conditions can act on the IGF-1 pathway, such as by binding (e.g., agonizing) IGF1R. Other compositions may act on the IGF-1 pathway by other mechanisms. The present disclosure also discloses related methods, kits, and pharmaceutical compositions for treating eye-related conditions.

The utility model relates to a radio-frequency therapeutic apparatus for meibomian gland dysfunction and dry eye. The radio-frequency therapeutic apparatus comprises an operating handle and a main machine body, the operating handle comprises a handheld rod and a radio frequency head; the radio frequency end of the radio frequency head is provided with at least two electrodes, an insulator is arranged between every two adjacent electrodes, and the connecting end of the radio frequency head is connected to the handheld rod. The electrode is capable of generating a radio frequency current. The radiofrequency head has the advantages that the radiofrequency end of the radiofrequency head abuts against the outer portion of the eyelid of a patient, radiofrequency current is applied to the eyelid through the electrode, oscillation of charged ions such as water containing polar molecules in eyelid tissue is promoted, and heat energy is generated through friction between the charged ions, so that the eyelid is heated, and abnormal meiboid blocked in meiboid glands is melted; the heat conduction speed is high, the heating depth is increased, and the treatment effect is improved. The radio frequency end of the radio frequency head is provided with at least two electrodes, the two electrodes apply radio frequency current to different positions of the eyelid at the same time, the applying uniformity of the radio frequency current is improved, the whole meibomian gland of the eyelid is evenly heated, and the dry eye treatment effect is improved.

The utility model discloses an auxiliary physiotherapy instrument for meibomian gland dysfunction, and relates to the technical field of treatment of meibomian gland related diseases in the ophthalmology department. Comprise two glasses frames forming the glasses, two glasses legs and a glasses beam between the two glasses frames, and non-light-transmitting lenses are arranged on the inner sides of the glasses frames; a face fitting type sealing structure is arranged on the side, facing the face, of the mirror frame, and the face fitting type sealing structure is fitted to the periphery of the eye socket of the face and forms a closed space covering the periphery of the eye socket of the face with the mirror frame and the non-light-transmitting lenses; an elastic contact ball is arranged on the side, facing the face, of the non-light-transmitting lens and used for elastically making contact with the tarsal parts of the eyes. A heating mechanism is arranged in the elastic contact ball and used for keeping the surface of the elastic contact ball at the temperature for hot compress of eyelids; an eye distance adaptive adjusting mechanism is arranged between the non-light-transmitting lens and the elastic contact ball and is used for supporting the elastic contact ball and adjusting the transverse position of the elastic contact ball on the inner side of the lens frame; and a vibratory massage driving mechanism is arranged on the glasses beam.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

A heated eye mask apparatus for therapeutic treatment of meibomian gland dysfunction, blepharitis, dry eye disease, and related ocular conditions. The apparatus comprises a body portion with adjustable straps and a pair of detachable eye covers releasably secured to the body portion via fastening mechanisms enabling positional adjustment. Each eye cover includes at least one heating element with multiple independently controllable heating zones, allowing targeted thermal therapy to specific periocular anatomical regions. The heating elements are powered by rechargeable batteries integrated within the body portion, providing cordless operation. Flexible tethers connect the eye covers to the body portion, providing mechanical retention and electrical connectivity. A control interface comprising user-actuatable buttons enables independent activation of heating zones. Alternative embodiments may include a steam generation system providing combined heat and moisture therapy. The adjustable configuration accommodates varying facial anatomies and enables customized treatment based on individual therapeutic requirements.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

This invention discloses the application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome, relating to the field of biomedical technology. The application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome. This invention is the first to discover the application of the Wnt-β-catenin pathway inhibitor LGK974 in the treatment of dry eye syndrome. LGK974, by inhibiting the Wnt-β-catenin pathway, can effectively protect meibomian gland acini and ducts, restoring normal lipid metabolism and secretion. In a NOD (Normally Ophthalmic Disorder) Sjögren's syndrome model, oral administration of 200-400 μg / kg / day of LGK974 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, alleviating morphological and functional damage to the meibomian glands. LGK974 provides a new targeted strategy for the treatment of dry eye syndrome, especially Sjögren's syndrome-related dry eye syndrome and meibomian gland dysfunction-related dry eye syndrome, and may become a potent and effective drug for the clinical treatment of dry eye in the future.

The invention relates generally to the field of medical devices and, more specifically, to a handheld device that stimulates the meibomian gland of the eyelid mechanically, and specifically stimulates the meibomian glands of the eyelid to treat Meibomian gland dysfunction, also known as “Dry eye” and chronic marginal eyelid inflammation.

The invention provides a composition containing AR-15512, a preparation method of the composition and application of the composition in eye diseases such as xerophthalmia, meibomian gland dysfunction, allergic conjunctivitis and eye pain.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof for the inhibition of CYP26B1. Aspects of the present disclosure also include methods of using the compounds in the treatment of diseases or conditions including, but not limited to, skin conditions, cancer, neurological conditions, heterotopic ossification (HO), progressive ossified fibrodysplasia (FOP), multiple osteochondroma, and ocular diseases or conditions, including meibomian gland dysfunction and dry eye disease.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof for inhibiting CYP26B1. Aspects of the present disclosure also include methods of using the compounds to treat diseases or disorders, including, but not limited to, skin disorders, cancer, neurological disorders, heterotopic ossification (HO), fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas, and diseases or disorders of the eye, including meibomian gland dysfunction and dry eye disease.

The present disclosure provides a method of treating keratoconjunctivitis sicca and / or meibomian gland dysfunction using an ophthalmic composition comprising a semifluorinated alkane, the method providing enrichment of the ophthalmic tissue for a semifluorinated alkane, and optionally delayed release of semi-fluorinated alkanes from enriched ocular tissue to the surface of cornea and / or conjunctiva and / or to meibomian glands.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

The invention relates to the technical field of meibomian gland image processing, in particular to a meibomian gland deletion grading method based on a convolutional neural network and a Transform technology. Obtaining a meibomian gland image data set, and introducing a fast forward algorithm to carry out restoration processing on the meibomian gland image data set so as to reduce the gland boundary ambiguity in the meibomian gland image caused by tear reflection and improve the sensitivity of the segmentation model to boundary features; constructing a multi-granularity meibomian gland segmentation model, inputting the processed meibomian gland image data set into the multi-granularity meibomian gland segmentation model, and training the multi-granularity meibomian gland segmentation model based on a convolutional neural network and a Transform technology; according to the meibomian gland image segmentation method, the meibomian gland image segmentation efficiency is improved, the robustness and consistency of the segmentation result are enhanced, and technical support is provided for rapid diagnosis and accurate evaluation of meibomian gland dysfunction.

According to the meibomian gland dysfunction treatment system and the control method, the equipment environment temperature and the host water outlet temperature are collected, a model is established in combination with the equipment heat exchange total thermal resistance, the actual temperature of the eye cup is accurately calculated, then the human body temperature and the man-machine heat exchange total thermal resistance are fused, and finally the steady-state temperature of the contact face of the eye cup and the human eyes is locked. Moreover, PID closed-loop control is adopted, temperature deviation in the heat exchange process of the equipment and the man-machine heat exchange process can be corrected in real time, a proportional link quickly responds to sudden fluctuation of the water flow temperature and the environment temperature, an integral link eliminates accumulated deviation such as continuous heat dissipation of a pipeline, a differential link prejudges the temperature change trend to avoid overshoot, and the heat exchange efficiency is improved. The temperature of the contact surface is always stabilized in a target range, the hot compress temperature is stabilized in a clinical effective interval, and the core target of treatment of lipid softening and gland opening expansion is realized.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.

Described herein are compositions and methods for increasing the amount of lipids secreted by the meibomian glands. Such compositions and methods can be used to treat meibomian gland dysfunction and conditions resulting therefrom.

This invention discloses a multi-dimensional quantitative assessment method and system combining meibomian gland morphology and function, belonging to the fields of ophthalmic diagnosis and artificial intelligence technology. It acquires color images of the eyelid margin, infrared images of the meibomian glands, and dynamic videos of gland expulsion upon pressure, inputting these into a dedicated AI analysis engine for processing. Employing an innovative anatomically guided backbone network and a meibomian gland region adaptive module, it achieves parallel automatic quantitative scoring across four dimensions: meibomian gland opening abnormality score, secretion characteristics score, expulsion capacity score, and morphological abnormality score based on gland segmentation loss rate. The four scores are summed to obtain a comprehensive total score, used for the graded diagnosis of meibomian gland dysfunction. By comparing changes in the patient's scores over time, it achieves macroscopic and microscopic evaluation of treatment efficacy. By integrating functional and morphological indicators into a unified automated quantitative system, it solves the problems of subjectivity and fragmentation in existing assessment methods, significantly improving the objectivity, comprehensiveness, and accuracy of diagnosis, and providing a reliable tool for individualized treatment and long-term management of MGD.

The presently disclosed subject matter is directed to compositions and methods for treating CaMKK2-mediated ophthalmic diseases, including but not limited to 1) ocular surface inflammatory diseases (OSIDs), including but not limited to ocular graft versus host disease, ocular cicatricial pemphigoid, vernal keratoconjunctivitis, allergic eye disease, meibomian gland dysfunction, aqueous tear deficiency (common dry eye disease), corneal scarring, and conjunctival scarring and fibrosis; 2) uveitis and other inflammatory diseases of the eye, including but not limited to keratitis, scleritis, iritis, iridocyclitis, intermediate uveitis, pars planitis, posterior uveitis, choroiditis, chorioretinitis, retinitis, or panuveitis of noninfectious, infectious, or idiopathic etiologies; and 3) “back of the eye” retinal diseases, which include dry age-related macular degeneration, neovascular age-related macular degeneration, diabetic retinopathy, retinal vascular diseases (e.g. retinal vein occlusion, retinal artery occlusion), and retinal degenerations and dystrophies, in a subject. Particularly, the disclosed compounds exhibit improvements over STO-609, a well characterized specific inhibitor of CaMKK2. The disclosed compounds exhibit enhanced aqueous solubility and formulation, as well as elimination of non-binding isomers during production. The disclosed inhibitor compounds can be used to effectively treat ophthalmic diseases, cancers, appetite disorders, systemic inflammatory diseases, and the like.

In some examples, a method for providing personalized treatment recommendations for Meibomian Gland Dysfunction (MGD) includes collecting, at a user device comprising one or more processors, sensor data from one or more sensors on a MGD treatment device being used for treatment of a user; supplying, at the user device, the sensor data to a machine learning model trained on training sensor data and training user outcome data; and adjusting, at the user device and based on an output from the machine learning model, one or more treatment parameters for treatment of the user with the MGD treatment device.